Bens, Annet
Dehlendorff, Christian
Friis, Søren
Cronin-Fenton, Deirdre
Jensen, Maj-Britt
Ejlertsen, Bent
Lash, Timothy L.
Kroman, Niels
Mellemkjær, Lene
Funding for this research was provided by:
Det Frie Forskningsråd (11-108395)
Article History
Received: 17 June 2019
Revised: 7 January 2020
Accepted: 23 January 2020
First Online: 17 February 2020
Ethics approval and consent to participate
: The study was approved by the Danish Data Protection Agency (J. no. 2012-41-0284). In Denmark, approvals from Ethical Committees are not required for register-based studies that do not involve biological samples.
: The study was approved by the Danish Data Protection Board. Data were available from the Danish Breast Cancer Group (ExternalRef removed), Statistics Denmark (ExternalRef removed) and the Research Service of Sundhedsdatastyrelsen (ExternalRef removed). R-code of analyses is available from the corresponding author upon request.
: Maj-Britt Jensen has received grants from AstraZeneca, Celgene and Novartis, and Bent Ejlertsen from NanoString, Novartis and Roche, both outside the submitted work. Lene Mellemkjær has an immediate family member employed at Novo Nordisk and has an immediate family member who owns stocks in Novo Nordisk. All other authors declared no conflicts of interest.
: This work was supported by the Danish Research Council for Independent Research [grant number 11-108395].